Table 1.
Baseline patient characteristics.
| Eptifibatide | First control | Second control | P-value | |
|---|---|---|---|---|
| (n = 54) | (n = 54) | (n = 54) | ||
| Age, median y (IQR) | 67 (59–73) | 68 (60–77) | 68 (59–77) | 0.55 |
| Female, no. (%) | 35 (64.8%) | 30 (55.6%) | 26 (48.1%) | 0.21 |
| Race, no. (%) | ||||
| Caucasian | 30 (55.6%) | 30 (55.6%) | 40 (74.1%) | 0.07 |
| African American | 13 (24.1%) | 14 (25.9%) | 10 (18.5%) | 0.63 |
| Asian/Pacific Islander | 2 (3.7%) | 2 (3.7%) | 0 (0%) | 0.37 |
| Other | 4 (7.4%) | 2 (3.7%) | 0 (0%) | 0.14 |
| Hispanic, no. (%) | 3 (5.6%) | 6 (12.5%) | 4 (7.4%) | 0.42 |
| ASPECTS, median (IQR) | 9 (8–10) | 9 (9–10) | 9 (8–10) | 0.08 |
| Pre-morbid mRS score, median (IQR) (n = 42*) | 0 (0–1) | 0 (0–1) | 0 (0–0) | 0.29 |
| Pre-morbid mRS 0–2 | ||||
| no. (%) | 40/42 (95.2%) | 36/42 (85.7%) | 39/42 (92.9%) | 0.24 |
| Baseline NIHSS, median (IQR) | 13 (9–19) | 16 (9–21) | 14 (9–20) | 0.61 |
| Wake-up stroke no. (%) | 15 (27.8%) | 20 (37.0%) | 8 (14.8%) | 0.03 |
| Last known well to arrival, median min (IQR) (N = 44*) | 461 (177–728) | 305 (132–596) | 281 (180–454) | 0.43 |
| Systolic blood pressure on arrival, median mmHg (IQR) (N = 51*) | 161 (130–189) | 156 (130–186) | 141 (125–165) | 0.14 |
| Platelet count, median (IQR) (N = 52*) | 236 (188–269) | 216 (181–279) | 220 (175–296) | 0.39 |
| International normalized ratio, median (IQR) (N = 41*) | 1.1 (1–1.2) | 1.2 (1.1–1.4) | 1.1 (1–1.2) | 0.39 |
| Hematocrit, median (IQR) (N = 47*) | 38.6 (36–41) | 38.5 (33.4–42.4) | 38.6 (36.3–43) | 0.76 |
| Site of occlusion, no. (%) | ||||
| Internal carotid artery | 29 (53.7%) | 19 (35.2%) | 14 (25.9%) | 0.010 |
| Middle cerebral artery | 36 (66.7%) | 39 (72.2%) | 40 (74.1%) | 0.68 |
| Tandem | 14 (25.9%) | 8 (14.8%) | 5 (9.3%) | 0.065 |
| Past Medical History, no. (%) | ||||
| Hypertension | 28 (51.9%) | 38 (70.4%) | 43 (79.6%) | 0.009 |
| Hyperlipidemia | 15 (27.8%) | 23 (42.6%) | 25 (46.3.%) | 0.13 |
| Diabetes | 15 (27.8%) | 15 (27.8%) | 17 (31.5%) | 0.89 |
| Prior Stroke/Transient ischemic attack | 12 (22.2%) | 6 (11.1%) | 11 (20.4%) | 0.30 |
| Atrial fibrillation | 4 (7.4%) | 17 (31.5%) | 15 (27.8%) | 0.0003 |
| Peripheral vascular disease | 4 (7.4%) | 3 (5.6%) | 3 (5.6%) | 0.89 |
| Tobacco use | 23 (42.6 %) | 19 (35.2%) | 14 (25.9%) | 0.18 |
| Prior antiplatelet and anticoagulation use | ||||
| Prior antiplatelet use, no. (%) | 12 (22.2%) | 20 (37.0%) | 19 (35.2%) | 0.23 |
| Prior aspirin use, no. (%) | 11 (20.4%) | 19 (35.2%) | 18 (33.3%) | 0.21 |
| Prior anticoagulation use, no. (%) | 5 (9.3%) | 12 (22.2%) | 7 (13.0%) | 0.13 |
| Thrombolysis administration | 14 (25.9%) | 20 (37.0%) | 16 (29.6%) | 0.44 |
| Suspected stroke etiology, no. (%) | ||||
| Large artery atherosclerosis | 19 (47.5%) | 5(12.5%) | 5 (12.5%) | 0.001 |
| Cardioembolism | 3 (7.5%) | 19(47.5%) | 16 (40.0%) | 0.001 |
| Other determined etiology/ undetermined etiology | 18 (42.9%) | 17 (40.5%) | 19 (45.2%) | 0.89 |
*
Number of patients in each study group. IQR: interquartile range, ASPECTS Alberta stroke program early CT score; mRS modified Rankin scale, and NIHSS National Institutes of Health Stroke Scale.